NL-OMON33127撤回2 期
Clinical Evaluation of the Edwards Lifesciences Monarc system for the treatment of Mitral Regurgitation - Evolution II
Edwards Lifesciences SA0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- functional mitral valve regurgitation
- •- ischemic or idiopathic cardiomyopathy
- •- NYHA Class II-IV
- •- Moderatre to severe mitral regurgitation
- •- Ability to perform 6 minute walk: 150-450 meters
排除标准
- •- subjects who are eligible for biventricular pacing leads within the coronary sinus
- •- active endocarditis
- •- prior mitral valve repair of replacement
- •- serum creatinine leven > 2.0mg/dl
- •- allergy to anticoagulation medications or contrast media
- •- aortic valve disease that requires surgical intervention
研究者
相似试验
已完成
不适用
Evaluation of the Clinical Performance of the 3M ESPE Lava Chairside Oral Scanner C.O.S.Dental crown due to cariesDRKS000002463M ESPE AG20
已完成
不适用
Endeavor primary percutaneous coronary intervention (PCI) studyAcute myocardial infarctionISRCTN66301072Medtronic Ltd (UK)100
已完成
不适用
A Clinical PeRformancE EVAluatIon of a new Medtronic Coronary Drug-Coated BaLloon Catheter<br>for the treatment of De Novo Lesions, In-Stent Restenosis and Small Vessel Disease in Coronary<br>Arteries; The PREVAIL study.coronary artery diseasecoronary stenosis1001108210003216NL-OMON48662Medtronic Trading NL BV30
进行中（未招募）
4 期
Are anti-viral medications (remdesivir) a safe and feasible drug to improve outcomes for those living with Long COVID?Post COVID-19 condition, post COVID syndrome and/or Long COVIDInfections and InfestationsISRCTN72940450niversity of Derby72
尚未招募
2 期
TO SEE THE EFFECT OF MUSTAK AND VACHA IN OBESITYCTRI/2022/10/046268ttarakhand Ayurved University